Dr. Dunlop, is a world-class neuroscientist and executive leader with over three decades of experience advancing therapeutic R&D for CNS disorders. He is a board member of Target-ALS and serves on scientific advisory boards for organizations including the ALS Association, Vigil Neuroscience, the Packard Center for ALS Research at Johns Hopkins, and the National Institute for Neurological Disorders and Stroke.

Previously, he served as CSO at Aliada Therapeutics (’25 acquired by Abbvie), CSO and Head of R&D at Neumora (’23 IPO). Prior to that, he served as COO at Pfizer, Vice President at Amgen, and Vice President and Head of the Neuroscience Innovative Medicine Unit at AstraZeneca. Dr. Dunlop is trained as a neuropharmacologist and his research focuses on protein quality control mechanisms, innate immunity, and mitochondrial dysfunction in neurodegenerative diseases such as ALS, Parkinson’s, and Alzheimer’s.